Citigroup Inc Rapt Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 22,567 shares of RAPT stock, worth $26,854. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,567

Previous 15,316 47.34%

Holding current value

$26,854

Previous $46,000 2.17%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.76 - $3.75 $12,761 - $27,191	7,251 Added 47.34%	22,567 $45,000
Q2 2024 Aug 12, 2024	BUY	$2.89 - $9.38 $29,061 - $94,325	10,056 Added 191.18%	15,316 $46,000
Q1 2024 May 10, 2024	SELL	$6.87 - $26.45 $233,133 - $897,580	-33,935 Reduced 86.58%	5,260 $47,000
Q4 2023 Feb 09, 2024	SELL	$11.28 - $25.46 $27,805 - $62,758	-2,465 Reduced 5.92%	39,195 $973,000
Q3 2023 Nov 09, 2023	SELL	$16.34 - $24.66 $47,320 - $71,415	-2,896 Reduced 6.5%	41,660 $692,000
Q2 2023 Aug 10, 2023	SELL	$16.06 - $21.61 $1.07 Million - $1.44 Million	-66,560 Reduced 59.9%	44,556 $833,000
Q1 2023 May 11, 2023	BUY	$17.19 - $30.8 $431,623 - $773,357	25,109 Added 29.19%	111,116 $2.04 Million
Q4 2022 Feb 09, 2023	BUY	$16.28 - $24.6 $333,056 - $503,266	20,458 Added 31.21%	86,007 $1.7 Million
Q3 2022 Nov 10, 2022	BUY	$17.96 - $30.46 $554,550 - $940,513	30,877 Added 89.05%	65,549 $1.58 Million
Q2 2022 Aug 10, 2022	BUY	$10.26 - $23.59 $206,031 - $473,710	20,081 Added 137.63%	34,672 $633,000
Q1 2022 May 12, 2022	SELL	$17.02 - $40.22 $921,292 - $2.18 Million	-54,130 Reduced 78.77%	14,591 $321,000
Q4 2021 Feb 10, 2022	BUY	$29.5 - $39.5 $1.9 Million - $2.54 Million	64,423 Added 1498.91%	68,721 $2.52 Million
Q3 2021 Nov 10, 2021	BUY	$29.86 - $39.47 $128,338 - $169,642	4,298 New	4,298 $133,000

Others Institutions Holding RAPT

# of Institutions

105

Shares Held

27.1M

Call Options Held

26.7K

Put Options Held

2.4K

View Full List

About RAPT Therapeutics, Inc.

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $35.3M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

More about RAPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account